68003-38-3
68003-38-3 structure
- Name: CTPI-2
- Chemical Name: 2-[(4-chloro-3-nitrophenyl)sulfonylamino]benzoic acid
- CAS Number: 68003-38-3
- Molecular Formula: C13H9ClN2O6S
- Molecular Weight: 356.73800
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2016-01-02 09:25:46
- Modify Date: 2025-08-27 23:37:16
-
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity[1][2].
| Name | 2-[(4-chloro-3-nitrophenyl)sulfonylamino]benzoic acid |
|---|---|
| Synonyms | einecs 268-121-3 |
| Description | CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
KD: 3.5 μM (SLC25A1)[1] |
| In Vivo | CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 (26 mg/kg; i.p.) inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC)[1]. CTPI-2 (50 mg/kg; i.p.; alternate days for 12 weeks) completely averts weight gain in the prevention study and leads to significant weight loss in the reversion study[2]. CTPI-2 prevents steatohepatitis and normalizes glucose tolerance. CTPI-2 lowers the levels of circulating IL-6 while increasing anti-inflammatory IL-4 and IL-10 and also reduced the monocyte chemoattractant protein-1 and monokine-induced by interferon-γ that attract neutrophils and monocytes. CTPI-2 regulates the citrate pool, the lipogenic and the gluconeogenic pathways[2]. Animal Model: C57BL/6J mice (HFD-fed mice)[2] Dosage: 50 mg/kg Administration: Alternate days via the intraperitoneal route for 12 weeks Result: Completely averted weight gain in the prevention study and led to significant weight loss in the reversion study. |
| References |
| Density | 1.66g/cm3 |
|---|---|
| Boiling Point | 564.8ºC at 760 mmHg |
| Molecular Formula | C13H9ClN2O6S |
| Molecular Weight | 356.73800 |
| Flash Point | 295.4ºC |
| Exact Mass | 355.98700 |
| PSA | 137.67000 |
| LogP | 4.42420 |
| Index of Refraction | 1.678 |
| Hazard Codes | Xn |
|---|---|
| HS Code | 2935009090 |
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |